Article info
PDFEditorial commentary
What should we do about vaccination of patients on anti-CD20 antibody therapy?
- Correspondence to Professor Takayoshi Shimohata, Neurology, Gifu University, Gifu 501-1194, Japan; shimohata{at}gmail.com
Citation
What should we do about vaccination of patients on anti-CD20 antibody therapy?
Publication history
- Received July 6, 2021
- Accepted July 7, 2021
- First published August 2, 2021.
Online issue publication
December 14, 2021
Article Versions
- Previous version (2 August 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage